Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.410
-0.090 (-2.57%)
At close: Jun 26, 2026, 4:00 PM EDT
3.395
-0.015 (-0.44%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Inventiva Employees
As of December 31, 2025, Inventiva had 77 total employees, including 69 full-time and 8 part-time employees. The number of employees decreased by 41 or -34.75% compared to the previous year.
Employees
77
Change (1Y)
-41
Growth (1Y)
-34.75%
Revenue / Employee
$103,094
Profits / Employee
-$5,400,017
Market Cap
772.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Allogene Therapeutics | 152 |
| Aura Biosciences | 113 |
| CytomX Therapeutics | 69 |
| Zevra Therapeutics | 61 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
| Design Therapeutics | 54 |
IVA News
- 12 days ago - Claret Capital Partners participates in €130m financing for Inventiva - GlobeNewsWire
- 12 days ago - Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development - GlobeNewsWire
- 15 days ago - Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing - GlobeNewsWire
- 18 days ago - Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents - GlobeNewsWire
- 24 days ago - Inventiva Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Inventia Resumes Trading Of Ordinary Shares On Euronext Paris - Nasdaq
- 25 days ago - Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris - GlobeNewsWire
- 25 days ago - Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout - GlobeNewsWire